Here are four notes:
1. Exogen has treated over 1 million patients since being FDA PMA approved in 1994.
2. The system uses low-intensity pulsed ultrasound to stimulate the body's natural healing process.
3. The new clinical research, Bioventus Observational Non-interventional Exogen Studies, will build on previous data to develop additional clinical knowledge of the product.
4. Bioventus Senior Vice President and Chief Science Offer Alessandro Pavesio said, "BONES represents a significant investment in developing epidemiologically grounded rigorous clinical evidence to support use of Exogen in fractures at risk."